🇺🇸 Recombinant human C1 esterase inhibitor in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 2
Most-reported reactions
- Lymphomatoid Papulosis — 1 report (50%)
- Transient Ischaemic Attack — 1 report (50%)
Frequently asked questions
Is Recombinant human C1 esterase inhibitor approved in United States?
Recombinant human C1 esterase inhibitor does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Recombinant human C1 esterase inhibitor in United States?
Shire is the originator. The local marketing authorisation holder may differ — check the official source linked above.